ABCD debate at the annual ABCD virtual meeting 18 December 2020
DOI:
https://doi.org/10.15277/bjd.2021.330Abstract
Speakers:
For the Motion: Dr Stephen Wheatcroft, Consultant Cardiologist and Professor of Cardiometabolic Medicine, University of Leeds, West Yorkshire
Against the Motion: Professor John Wilding. Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, Clinical Sciences Centre, Aintree University Hospital, Liverpool
References
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925
Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol 2018;6(9):691–704. https://doi.org/10.1016/S2213-8587(18)30141-4
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380(4): 347–57. https://doi.org/10.1056/NEJMoa1812389
Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020;383: 1425–35. https://doi.org/10.1056/NEJMoa2004967
Heerspink H, Stefansson B, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383: 1436–46. https://doi.org/10.1056/NEJMoa2024816
McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303
Packer M, Anker S, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383: 1413–24. https://doi.org/10.1056/NEJMoa2022190
Summary of Product Characteristics. Forxiga 5 mg and 10 mg film coated tablets. www.medicines.org.uk/emc/product/2865/smpc
Dashora U, Gallagher A, Dhatariya K, Winocour P, Gregory R, ABCD Committee. Association of British Clinical Diabetologists (ABCD) position statement on the risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors. Br J Diabetes 2016;16(4):206–9. http://dx.doi.org/10.15277/bjd.2016.112
Dashora U, on behalf of CaReMe UK. Manage diabetes and comorbidities with a joined-up strategy. May 2021. https://www.guidelinesinpractice.co.uk/diabetes/manage-diabetes-and-comorbidities-with-a-joined-up-strategy/456004.article
Dashora U, Gregory R, Winocour P, et al. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes. Clin Med 2021;21(3):204–10. https://doi.org/10.7861/clinmed.2021-0045
Published
Issue
Section
License
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
